Surrozen (SRZN) Set to Announce Earnings on Tuesday

Surrozen (NASDAQ:SRZN) is set to post its quarterly earnings results on Tuesday, April 16th.

Surrozen Trading Down 3.2 %

SRZN opened at $10.73 on Monday. The stock has a fifty day simple moving average of $12.21 and a two-hundred day simple moving average of $9.19. Surrozen has a 12-month low of $4.50 and a 12-month high of $16.19.

Insiders Place Their Bets

In other news, Director Tim Kutzkey acquired 193,548 shares of the firm’s stock in a transaction on Thursday, April 4th. The stock was acquired at an average price of $15.50 per share, for a total transaction of $2,999,994.00. Following the completion of the acquisition, the director now owns 332,885 shares in the company, valued at $5,159,717.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 35.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Surrozen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Surrozen by 3.2% during the third quarter. Vanguard Group Inc. now owns 487,278 shares of the company’s stock valued at $984,000 after acquiring an additional 15,299 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Surrozen by 284.6% during the first quarter. Renaissance Technologies LLC now owns 102,298 shares of the company’s stock valued at $62,000 after acquiring an additional 75,700 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Surrozen during the first quarter valued at $377,000. Millennium Management LLC bought a new position in shares of Surrozen during the fourth quarter valued at $72,000. Finally, FMR LLC bought a new position in shares of Surrozen during the second quarter valued at $744,000. 66.57% of the stock is currently owned by institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.